Squamous cell carcinoma of the penis is a rare malignancy among men in North America and Europe with an incidence of <1 per 100,00 men. Of all genitourinary cancers, penile carcinoma has the potential to jeopardize sexual function the most.
To evaluate the usefulness of radiological re-staging after 2 and 4 cycles of NAC, the impact of re-staging on further patient management and the correlation between clinical and the final pathological tumor stage at radical cystectomy.
Phillip Koo: Welcome to UroToday. We are here today at Tulane University Cancer Center, taking a look at the various components that it takes to run a successful theranostics program. We are very fortunate to have with us today, Dr. Kendra Harris, who is the Chair of Radiation/Oncology at Tulane. And we are going to […]
Phillip Koo: So Mr. Rowe, thank you very much for letting us participate in your therapy today. Can you tell us a little bit about how you feel after the treatment? Mr. Monroe: I feel like I did before she administered the drug, it was a very easy, routine thing. She flushed it out with […]
Telix announces collaboration with Lightpoint Medical to explore molecularly targeted radiation and Lightpoint SENSEI® in radioguided surgery (RGS) San Francisco, CA (UroToday.com) — Telix is pleased to announce it has signed a strategic collaboration agreement with UK-based Lightpoint Medical (‘Lightpoint’), a leading medical device company developing cancer detection tools for minimally-invasive and robot-assisted surgery. Under the collaboration the two […]
Kendra Harris: Now, if you would do us a favor, we need to do a timeout. So if you would say your name and date of birth. So first, I’m going to carefully check that I like your IV. All of these are filled with saltwater. Mr. Monroe: Okay. Kendra Harris: Typically, I’ll check with […]
Early-phase clinical trials are a treatment option for patients with metastatic bladder cancer (mBC). However, Patients enrolled in these trials have already been exposed to toxicity from prior therapies and developed a poor performance status making it challenging to identify patients who are likely to benefit.
In CheckMate -274, Opdivo nearly doubled median disease-free survival compared to placebo in the intent-to-treat population1 Opdivo is now approved in earlier stages of disease for three types of cancer, including the first and only PD-1 inhibitor approved for urothelial carcinoma in the adjuvant setting San Francisco, CA (UroToday.com) — Bristol Myers Squibb announced that Opdivo®(nivolumab) 240 mg every two […]
Complete clearance during index ERCP for choledocholithiasis is not always successful and biliary stenting is commonplace. Strategies vary between temporary stent placement (TSP) with interval ERCP or permanent stent placement (PSP) and watchful waiting for recurrent biliary obstruction (RBO).
Urinary stone disease is a common disease with a prevalence of 4.7% in Germany. The incidence increased over the last decades, and recurrence rates are up to 50% in the first 5 years after diagnosis.
